With dozens of biotech firms and research labs around the globe racing to come up with a vaccine for the novel coronavirus that has paralyzed the world since March, a couple of front runners have emerged. Moderna announced last week that peer review had confirmed the early stages of its trials had been successful at triggering an immune response, and had done so safely and with no seriously adverse side effects.
Now, less than a week later, Oxford University has announced that its early trials were also successful - with the addition that at least a million doses could be ready to go by September.